Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CalciMedica Q3 2026 Results: Net Loss of $1.7M, Loss Narrows

CalciMedica reported a net loss of $4.35 million for the nine months ended September 30, 2026, a significant improvement from the $18.80 million loss in the prior year period, primarily driven by a $10.5 million gain from the change in fair value of financial instruments. Total operating expenses decreased to $14.37 million from $18.74 million, while the company strengthened its cash position through private placements and warrant exercises.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.1
Net income-1.7-7.8
EPS (diluted, $ a share)$-0.24$-2.59

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-4.3%
Source

10-Q filed with the SEC, NASDAQ: CALC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CalciMedica, Inc.: key numbers

Share price
$1.19Close, Nov 16
Market cap
$8.21M
Shares outstanding
6.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CalciMedica, Inc.

All →
7:15 AM ET 8-K
Financial Results

CalciMedica Financial Results

CalciMedica reported third quarter 2026 financial results, ending the period with $13.8 million in cash which is expected to fund operations into the second half of 2027. The company highlighted clinical progress in its pulmonary hypertension and acute pancreatitis programs, with Phase 1b data for Auxora expected in mid-2027. Additionally, the company completed a 1-for-5 reverse stock split in August 2026 to regain Nasdaq compliance.

Term
3 years

“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies.”

Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica
4:47 PM ET 8-K
Leadership Change

CalciMedica Leadership Change

Stephen Bardin, the Chief Financial Officer, principal accounting officer, and principal financial officer of CalciMedica, Inc., has resigned to pursue another professional opportunity. The resignation is effective immediately following the filing of the company's Quarterly Report on Form 10-Q for the period ended September 30, 2026, and was not due to any disagreement with the company.

4:07 PM ET 8-K
Other 8-K Filing

CalciMedica Other 8-K Filing

CalciMedica filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $25 million of its common stock. The sales may occur from time to time through H.C. Wainwright & Co. under an existing offering agreement. As of this filing, no shares have been sold and no proceeds have been received.

Counterparty
H.C. Wainwright & Co.
4:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice

CalciMedica Nasdaq/NYSE Compliance Notice

CalciMedica has regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on March 16, 2026, and now has no outstanding deficiency notices from the exchange.

Counterparty
Nasdaq

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.